ICR urges continued negotiation after NICE rejection of olaparib for early breast cancer 10 Nov 2022 The Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer. Find out more Show/Hide
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021 Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial. Find out more Show/Hide
Ovarian cancer drug offers new genetically targeted approach against range of cancers 23 Apr 2021 A type of drug used against ovarian and breast cancers could offer a brand new targeted approach for treating a range of cancers with particular genetic defects, including a common form of kidney cancer. Find out more Show/Hide